Today, we're exploring the transformative potential of AI in biopharma—separating hype from reality, and zooming in on the complexities of single-cell omics data.

Our guest is Parashar Dhapola, co-founder and CEO of Nygen Analytics, a Lund-based startup spun out from Sweden's vibrant single-cell genomics ecosystem. With a PhD in computational genomics from Lund University, Parashar has pioneered efficient algorithms for analyzing millions of cells, turning raw data into actionable insights for drug discovery.

Join us as we discuss where AI truly delivers in biopharma, the persistent gaps in exploratory data analytics, and the critical bottlenecks in single-cell annotation. In a world abounding in AI hype, Parashar helps us cut through the noise and point out paths to data driven success.

• 01:00 Meet Parashar Dhapola
• 05:45 AI in biopharma
• 09:29 AI automation vs. new capabilities
• 11:28 What makes single-cell omics data different
• 18:46 Risks of incorrect cell annotation
• 34:37 Future of single-cell analytics

This episode is produced with the support of Nygen Analytics. Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• CyteType - AI powered cell type annotation
• Behind the Cure51 deal: Is NVIDIA becoming biotech’s AI infrastructure?
• The past, present, and future of genome sequencing

This week we welcome Magdalena Tyrpien, CEO, Co-Founder and President of Nionyx Bio, just days after the company took first place in the BIO-Europe Spring Startup Spotlight competition in Lisbon.

With a background that includes leading Forge Biologics through its $620 million acquisition, Magdalena is now steering Nionyx toward a bold new chapter in gene therapy for kidney disease. In this episode we explore her journey into biotech, the science behind Nionyx’s proprietary AAV capsid platform and Kidney Atlas, what it took to win the Startup Spotlight, and what the victory means for the young company’s future.

· 01:25 – Meet Magdalena Tyrpien

· 07:10 – The Nionyx mission

· 15:29 – The 2026 BIO-Europe Spring Startup Spotlight

· 22:23 – Looking forward and future milestones

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• Lisbon is calling: the BIO-Europe Startup Spotlight returns in March 2026
• BIO-Europe Spring 2026: partnership event brings funding hope to biotechs
• BIO-Europe partnering: Australian biotech companies share their experiences

Today, we welcome Dr Rosanne Dunn, Chief Scientific Officer and co-founder of HaemaLogiX, an Australian clinical-stage biotech company that's developing next-generation immunotherapies for multiple myeloma and other plasma cell disorders.

HaemaLogiX is taking a precision approach by targeting novel antigens that are expressed exclusively on malignant plasma cells, sparing healthy ones. Recent peer-reviewed research has validated KMA and LMA as high-value targets, reinforcing the company's unique positioning in the field.

Rosanne shares her journey from antibody engineering to building HaemaLogiX, the science behind their differentiated targets, the latest clinical and preclinical progress, and her perspectives on the future of immunotherapy for blood cancers as the company gears up for key milestones, including a planned IPO later this year.

• 01:15 Meet Rosanne Dunn
• 07:52 HaemalogiX's mission and novel antigens
• 09:53 Overview of multiple myeloma and its symptoms
• 12:19 Targeting malignant plasma cells while sparing normal ones
• 19:25 Recent Peer-Reviewed Research
• 26:08 Synergy with IMiDs like Revlimid
• 29:08 Potential patient impact and quality of life
• 35:05 Planned IPO in 2026 and funding needs

Interested in being a sponsor of an episode of our podcast? Discover how you can get involved here!

Stay updated by subscribing to our newsletter

To dive deeper into the topic:

• 5 cancers that immunotherapy can cure
• BIO-Europe partnering: Australian biotech companies share their experiences
• How are R&D Tax Incentives shaping Australia’s biotech future?